Medicxi Ventures (UK) LLP, operating as Medicxi, is a London-based venture capital firm specializing in life sciences investments. Established in 2016 by the former life sciences team from Index Ventures, the firm focuses on biotech and pharmaceuticals, backing companies from early discovery through to clinical proof-of-concept and beyond.
Medicxi employs an "asset-centric" investment strategy, creating and funding virtual startups around promising therapeutic assets to accelerate development of novel treatments for unmet medical needs. It has raised multiple funds totaling over €2 billion, with backing from major players including GlaxoSmithKline, Johnson & Johnson Innovation, Novartis, and Verily. The firm maintains offices in London, Geneva, and Jersey.
Portfolio successes include exits like Vicebio (acquired by Sanofi), Versanis (Eli Lilly), and Centessa Pharmaceuticals, alongside ongoing support for biotechs in oncology, neurology, and immunology.
Also known as Medicxi.
$38/ADS cash + up to $9 CVR (max $47/sh); upfront equity ~$6.3B (CVR ~$1.5B). Lead OX2R agonist cleminorexton showed positive Phase 2a for narcolepsy and idiopathic hypersomnia. Close expected Q3
